Evidence map›Paper›PMID 29450713›Full record

ArticleEuropean radiology2018

Radiomic signature as a diagnostic factor for histologic subtype classification of non-small cell lung cancer.

Xinzhong Zhu, Di Dong, Zhendong Chen, Mengjie Fang, Liwen Zhang, Jiangdian Song, Dongdong Yu, Yali Zang, Zhenyu Liu, Jingyun Shi and 1 more

Abstract read
PubMed Publisher
In one paragraph

Article in European radiology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 105 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
105citing papers in PubMed, 3 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

105 citing papers in PubMed, 3 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Trial
  5. Trial
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article

45 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Xinzhong ZhuSchool of Life Science and Technology, XIDIAN University, Xi'an, Shanxi, China. zxz@zjnu.edu.cn.
Di DongCAS Key Lab of Molecular Imaging, Institute of Automation, Chinese Academy of Sciences, Beijing, China. di.dong@ia.ac.cn.
Zhendong ChenCAS Key Lab of Molecular Imaging, Institute of Automation, Chinese Academy of Sciences, Beijing, China.
Mengjie FangCAS Key Lab of Molecular Imaging, Institute of Automation, Chinese Academy of Sciences, Beijing, China.
Liwen ZhangCAS Key Lab of Molecular Imaging, Institute of Automation, Chinese Academy of Sciences, Beijing, China.
Jiangdian SongCAS Key Lab of Molecular Imaging, Institute of Automation, Chinese Academy of Sciences, Beijing, China.
Dongdong YuCAS Key Lab of Molecular Imaging, Institute of Automation, Chinese Academy of Sciences, Beijing, China.
Yali ZangCAS Key Lab of Molecular Imaging, Institute of Automation, Chinese Academy of Sciences, Beijing, China.
Zhenyu LiuCAS Key Lab of Molecular Imaging, Institute of Automation, Chinese Academy of Sciences, Beijing, China.
Jingyun ShiDepartment of Radiology, Shanghai Pulmonary Hospital, Tongji University School of Medicine, Tongji, China. shijingyun89179@126.com.
Jie TianSchool of Life Science and Technology, XIDIAN University, Xi'an, Shanxi, China.ORCID http://orcid.org/0000-0003-0498-0432

Funding

Beijing Municipal Science and Technology Commission Z161100002616022National Key R&D Program of China 2017YFA0205200National Key R&D Program of China 2017YFC1308700National Key R&D Program of China 2017YFC1308701National Key R&D Program of China 2017YFC1309100National Natural Science Foundation of China 61231004National Natural Science Foundation of China 81227901National Natural Science Foundation of China 81501549National Natural Science Foundation of China 81501616National Natural Science Foundation of China 81527805National Natural Science Foundation of China 81671851National Natural Science Foundation of China 81771924the Instrument Developing Project YZ201502The Science and Technology Service Network Initiative of the Chinese Academy of Sciences KFJ-SW-STS-160
6 · The paper itself

Abstract

objectivesTo distinguish squamous cell carcinoma (SCC) from lung adenocarcinoma (ADC) based on a radiomic signature

methodsThis study involved 129 patients with non-small cell lung cancer (NSCLC) (81 in the training cohort and 48 in the independent validation cohort). Approximately 485 features were extracted from a manually outlined tumor region. The LASSO logistic regression model selected the key features of a radiomic signature. Receiver operating characteristic curve and area under the curve (AUC) were used to evaluate the performance of the radiomic signature in the training and validation cohorts.

resultsFive features were selected to construct the radiomic signature for histologic subtype classification. The performance of the radiomic signature to distinguish between lung ADC and SCC in both training and validation cohorts was good, with an AUC of 0.905 (95% confidence interval [CI]: 0.838 to 0.971), sensitivity of 0.830, and specificity of 0.929. In the validation cohort, the radiomic signature showed an AUC of 0.893 (95% CI: 0.789 to 0.996), sensitivity of 0.828, and specificity of 0.900.

conclusionsA unique radiomic signature was constructed for use as a diagnostic factor for discriminating lung ADC from SCC. Patients with NSCLC will benefit from the proposed radiomic signature. KEY POINTS: • Machine learning can be used for auxiliary distinguish in lung cancer. • Radiomic signature can discriminate lung ADC from SCC. • Radiomics can help to achieve precision medical treatment.

Indexed as

AdenocarcinomaAdenocarcinoma of LungAdultAgedArea Under CurveCarcinoma, Non-Small-Cell LungCarcinoma, Squamous CellDiagnosis, DifferentialFemaleHumansLung NeoplasmsMaleMiddle AgedRadiographic Image Interpretation, Computer-AssistedRetrospective StudiesROC CurveAenocarcinomaDiagnostic imagingRegression analysisROC curveSquamous cell carcinoma

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.